Aug. 24 (Yonhap) — Hanmi Pharm. Co., a South Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won (US$2.3 billion) licensing deal with Genentech Inc., a U.S.-based member of the Roche Group, for an obesity drug candidate designed to reduce body fat while preserving and increasing muscle mass
Hanmi Pharm has signed an exclusive licensing agreement with Genentech for the development, manufacturing and commercialization of its novel metabolic treatment candidate HM17321, a long-acting uro-cortin-2 (UCN2) analog, for obesity and related conditions, including type 2 diabetes, the company said in a press release
Under the agreement, Genentech will have exclusive rights to research, develop, manufacture and commercialize HM17321 worldwide except in South Korea. Hanmi will retain the rights to the drug candidate in South Korea, it said
“By licensing this next-generation investigational therapy with first-in-class potential from Hanmi, Roche and Genentech will pursue a differentiated approach to selectively reduce fat mass while improving both muscle mass and muscle function,” Boris L. Zaitra, head of Roche Corporate Business Development, said in the release
Hanmi Pharm said it will continue its efforts to develop innovative medicines that offer more fundamental and differentiated therapeutic benefits to patients
In November last year, Hanmi received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 1 clinical trial of HM17321, and the trial is currently underway, the company said
Hanmi will be responsible for completing the Phase 1 trial, after which Genentech will take over development beginning with Phase 2, it said
Articles with issue keywords
Most Liked
- Enhypen returns as six-member group with new EP, ‘The Sin: Bliss’
- NCT Dream renews contract as full group with SM Entertainment
Suspense thriller ‘Mousetrap’ reinvents Korean folktale: director
- Seventeen’s Vernon to drop new song marking enlistment
(URGENT) Trump says N. Korea’s Kim has responded to him
Most Saved
(LEAD) Lee reaffirms push to retake wartime operational control of troops during his term
- Hanwha wins U.S. Army contract for K9 self-propelled howitzer prototypes
Suspense thriller ‘Mousetrap’ reinvents Korean folktale: director
- Chinese national gets 20 years for hacking accounts of BTS’ Jungkook, others
(LEAD) Trump says N. Korea’s Kim has responded to his dialogue overture
Most ViewedAll Categories
(2nd LD) An Se-young captures 2nd career badminton world title
S. Korea’s alcoholic beverage output falls to 27-year low in 2025 amid shifting drinking trends
(LEAD) An Se-young captures 2nd career badminton world title
No signs of additional deployment of N. Korean troops to Russia detected: S. Korean military
(LEAD) Gov’t, ruling party share need to relax tax rule for single-home owners not living in property
Most Viewed More
Most Viewed Photos
